Brief: Genocea Biosciences Expects That Its Existing Cash And Cash Equivalents Are Sufficient To Support Its Operations Into Q1 Of 2021
13/02/2020 12:29
Feb 13 (Reuters) - Genocea Biosciences Inc GNCA.O :
* GENOCEA BIOSCIENCES INC - EXPECTS THAT ITS EXISTING CASH
AND
CASH EQUIVALENTS ARE SUFFICIENT TO SUPPORT ITS OPERATIONS INTO
Q1 OF 2021
* GENOCEA BIOSCIENCES QTRLY LOSS PER SHARE $0.34
Source text for Eikon: ID:nGNX4sFLm
Further company coverage: GNCA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Genocea Biosciences
See all newsBluebird, Chimerix, Clovis have under 6 months of cash left - Truist
Genocea Biosciences plunges as it winds down operations
Brief: Genocea Announces Wind Down Of Operations And Delisting From Nasdaq
Genocea Biosciences Inc reports results for the quarter ended in March - Earnings Summary
U.S. STOCKS ON THE MOVE-Oppenheimer Holdings, IES Holdings Inc, Avantor Inc